{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:37:28Z","timestamp":1790095048364,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006127.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000}}],"reference-count":211,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006127.pub3","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:33:26Z","timestamp":1679981606000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Blood pressure control for diabetic retinopathy"],"prefix":"10.1002","volume":"2023","author":[{"given":"Diana V","family":"Do","sequence":"additional","affiliation":[{"name":"Byers Eye Institute; Stanford University School of Medicine; Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Johns Hopkins Bloomberg School of Public Health; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A","family":"Abariga","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Johns Hopkins Bloomberg School of Public Health; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Sleilati","sequence":"additional","affiliation":[{"name":"Clemenceau Medical Center; Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Swaroop","family":"Vedula","sequence":"additional","affiliation":[{"name":"Johns Hopkins University; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute; Johns Hopkins University School of Medicine; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate Blood Pressure Control in NIDDM (ABCD) Trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ncpneph0559","article-title":"Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial","volume":"3","author":"Schrier","year":"2007","journal-title":"Nature Clinical Practice Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0272-6386(12)70236-6","article-title":"Appropriate Blood Pressure Control in Type II Diabetes (ABCD Trial): implications for complications","volume":"20","author":"Schrier","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub3-BIB0005|cit5","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0007|cit7","first-page":"Doc No 104","article-title":"The ABCD (Appropriate Blood Pressure Control in Diabetes) Trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes","author":"Savage","journal-title":"Online Journal of Current Clinical Trials"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ncpneph0559","article-title":"Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial","volume":"3","author":"Schrier","year":"2007","journal-title":"Nature Clinical Practice Nephrology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjhyper.2006.05.011","article-title":"Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes","volume":"19","author":"Estacio","year":"2006","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"10889","DOI":"10.2337\/dc16-0024","article-title":"Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study","volume":"39","author":"Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archophthalmol.2009.310","article-title":"Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy","volume":"128","author":"Ambrosius","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjcard.2007.03.028","article-title":"Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)","volume":"99","author":"Chew","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1011499","article-title":"Update of the ACCORD Eye Study","volume":"364","author":"Chew","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/IAE.0b013e318286c952","article-title":"Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity","volume":"33","author":"Gangaputra","year":"2013","journal-title":"Retina"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc12-1311","article-title":"Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial","volume":"36","author":"Gerstein","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ajo.2017.12.007","article-title":"Lack of association between thiazolidinediones and incidence and progression of diabetic eye disease: The ACCORD Eye Study","volume":"187","author":"Gower","year":"2018","journal-title":"American Journal of Ophthalmology"},{"issue":"9739","key":"10.1002\/14651858.CD006127.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/ki.2011.415","article-title":"Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients","volume":"81","author":"Ismail-Beigi","year":"2012","journal-title":"Kidney International"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amjcard.2007.03.027","article-title":"Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design","volume":"99","author":"Sullivan","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2431-9-79","article-title":"Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT)","volume":"9","author":"Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group","year":"2009","journal-title":"BMC Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00125-017-4538-2","article-title":"The Adolescent Cardio-Renal Intervention Trial (AdDIT): retinal vascular geometry and renal function in adolescents with type 1 diabetes","volume":"61","author":"Benitez-Aguirre","year":"2018","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/dme.13299","article-title":"Banting Memorial Lecture 2016 Reducing lifetime risk of complications in adolescents with Type 1 diabetes","volume":"34","author":"Dunger","year":"2017","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpeds.2016.06.049","article-title":"Social determinants of health are associated with modifiable risk factors for cardiovascular disease and vascular function in pediatric type 1 diabetes","volume":"177","author":"Inman","year":"2016","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diabres.2016.01.031","article-title":"Assessing social determinants of health in a pediatric diabetes clinical research trial: are recruited subjects representative of the larger clinical population","volume":"113","author":"Inman","year":"2016","journal-title":"Diabetes Research and Clinical Medicine"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2337\/dc14-0700","article-title":"Early atherosclerosis relates to urinary albumin excretion and cardiovascular risk factors in adolescents with type 1 diabetes: Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT)","volume":"37","author":"Maftei","year":"2014","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1002\/14651858.CD006127.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1703518","article-title":"ACE inhibitors and statins in adolescents with type 1 diabetes","volume":"377","author":"Marcovecchio","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"378","key":"10.1002\/14651858.CD006127.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(11)60698-3","article-title":"Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial","volume":"9","author":"Griffin","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-8587(19)30349-3","article-title":"Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster randomised trial","volume":"7","author":"Griffin","year":"2019","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijo.0801420","article-title":"The ADDITION Study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening","volume":"Suppl 3","author":"Lauritzen","year":"2000","journal-title":"International Journal of Obesity"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc13-1544","article-title":"Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: The ADDITION-Europe Study","volume":"37","author":"Sandbaek","year":"2014","journal-title":"Diabetes Care"},{"issue":"64","key":"10.1002\/14651858.CD006127.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20640","article-title":"A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study","volume":"20","author":"Simmons","year":"2016","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s0125-013-3011-0","article-title":"Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial","volume":"56","author":"Van den Donk","year":"2013","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e3111","DOI":"10.1002\/dmrr.3111","article-title":"Intensive versus standard multifactorial cardiovascular risk factor control in screen-detected type 2 diabetes: 5-year and longer-term modelled outcomes of the ADDITION-Leicester study","volume":"35","author":"Webb","year":"2019","journal-title":"Diabetes and Metabolism Research Review"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-5491.2005.01596.x","article-title":"ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline","volume":"22","author":"ADVANCE Collaborative Group","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"9590","key":"10.1002\/14651858.CD006127.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD006127.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s001250100612","article-title":"Study rationale and design of ADVANCE: Action in Diabetes and Vascular Disease - preterax and diamicron MR controlled evaluation","volume":"44","author":"ADVANCE Management Committee","year":"2001","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00125-009-1457-x","article-title":"Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"52","author":"Beulens","year":"2009","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1046\/j.1440-1681.2001.03581.x","article-title":"Blood pressure lowering in diabetes: a brief review of current evidence and description of a new trial","volume":"28","author":"Patel","year":"2001","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000354417.70192.be","article-title":"Blood pressure and glucose control in subject with diabetes: new analysis from ADVANCE","volume":"27","author":"Poulter","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/dc07-1657","article-title":"Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study","volume":"31","author":"Stolk","year":"2008","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cct.2006.08.011","article-title":"Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus","volume":"28","author":"Stolk","year":"2007","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0197-2456(03)00028-X","article-title":"The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT)","volume":"24","author":"BENEDICT Group","year":"2003","journal-title":"Controlled Clinical Trials"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"Article ID 1063","DOI":"10.1155\/2010\/106384","article-title":"Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the Benedict trial","volume":"2010","author":"Ruggenenti","year":"2010","journal-title":"Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0050|cit50","first-page":"284","article-title":"Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial","volume":"25","author":"Chase","year":"1993","journal-title":"Annals of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1464-5491.2010.03210.x","article-title":"Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme","volume":"28","author":"Sjolie","year":"2011","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics","volume":"6","author":"DIRECT Programme Study Group","year":"2005","journal-title":"Journal of Renin-Angiotensin-Aldosterone System"},{"issue":"9647","key":"10.1002\/14651858.CD006127.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sjolie","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1464-5491.2001.00441.x","article-title":"Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition","volume":"18","author":"Chaturvedi","year":"2001","journal-title":"Diabetes Medicine"},{"issue":"9095","key":"10.1002\/14651858.CD006127.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"issue":"9068","key":"10.1002\/14651858.CD006127.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","author":"EUCLID Study Group","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0065|cit65","first-page":"949","article-title":"Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus","volume":"161","author":"Sjolie","year":"1999","journal-title":"Ugeskrift for Laeger"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0161-6420(97)30327-3","article-title":"Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study","volume":"104","author":"Sjolie","year":"1997","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD006127.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinternmed.2011.276","article-title":"Home blood pressure management and improved blood pressure control: results from a randomized controlled trial","volume":"171","author":"Bosworth","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ahj.2007.03.004","article-title":"Hypertension Intervention Nurse Telemedicine Study (HINTS): testing a multifactorial tailored behavioral\/educational and a medication management intervention for blood pressure control","volume":"153","author":"Bosworth","year":"2007","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamaophthalmol.2013.81","article-title":"Progression of diabetic retinopathy in the Hypertension Intervention Nurse Telemedicine Study","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"e000123","DOI":"10.1136\/bmjdrc-2015-000123","article-title":"Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial","volume":"4","author":"Sasako","year":"2016","journal-title":"BMJ Open Diabetes Research and Care"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s2213-8587(17)30327-3","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"5","author":"Ueki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1447-0594.2011.00808.x","article-title":"Long-term multiple risk factor interventions in Japanese elderly diabetic patients: The Japanese Elderly Diabetes Intervention Trial\u2013study design, baseline characteristics and effects of intervention","volume":"12","author":"Araki","year":"2012","journal-title":"Geriatrics & Gerontology International"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/EDE.0b013e318281725e","article-title":"Fruit intake and incident diabetic retinopathy with type 2 diabetes","volume":"24","author":"Tanaka","year":"2013","journal-title":"Epidemiology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1447-0594.2011.00821.x","article-title":"Prevalence and risk factors for diabetic maculopathy, and its relationship to diabetic retinopathy in elderly Japanese patients with type 2 diabetes mellitus","volume":"12","author":"Yamamoto","year":"2012","journal-title":"Geriatrics and Gerontology International"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1447-0594.2011.00822.x","article-title":"Long-term risk factors for diabetic retinopathy and diabetic maculopathy in elderly Japanese patients with type 2 diabetes mellitus","volume":"12","author":"Yamamoto","year":"2012","journal-title":"Geriatrics and Gerontology International"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2796.2003.01192.x","article-title":"Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study","volume":"254","author":"Knudsen","year":"2003","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00918480","article-title":"Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy","volume":"228","author":"Larsen","year":"1990","journal-title":"Graefe's Archive of Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.27.1.95","article-title":"Closing the gap: effect of diabetes care management on glycemic control among low-income ethnic minority populations.","volume":"27","author":"California Medi-Cal Type 2 Diabetes Study Group","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2337\/diacare.28.12.2819","article-title":"Decreasing the risk of diabetic retinopathy in a study of case management","volume":"28","author":"Pettitt","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1056-8727(02)00188-5","article-title":"Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients. A pilot study","volume":"16","author":"Pradhan","year":"2002","journal-title":"Journal of Diabetes and Its Complications"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1464-5491.2002.00701.x","article-title":"Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus\u2014a randomized prospective study","volume":"19","author":"Rachmani","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ophtha.2006.06.003","article-title":"The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus.\u00a0The Renin-Angiotensin System Study","volume":"113","author":"Klein","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2337\/diabetes.54.2.527","article-title":"The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. The Renin-Angiotensin System Study","volume":"54","author":"Klein","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3317\/jraas.2002.048","article-title":"ACE-I and ARBs in early diabetic retinopathy","volume":"3","author":"Mauer","year":"2002","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","article-title":"Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"24","author":"Haller","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"e000810","DOI":"10.1161\/JAHA.114.000810","article-title":"The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation","volume":"3","author":"Menne","year":"2014","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/HJH.0b013e328351856d","article-title":"Prevention of microalbuminuria in patients with type 2 diabetes and hypertension","volume":"30","author":"Menne","year":"2012","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00125-017-4739-3","article-title":"A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study","volume":"62","author":"Gaede","year":"2019","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.2337\/dc07-2452","article-title":"Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes","volume":"31","author":"Gaede","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"Gaede","year":"2016","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9153","key":"10.1002\/14651858.CD006127.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006127.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4158\/EP.12.S1.89","article-title":"Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study","volume":"12","author":"Vaag","year":"2006","journal-title":"Endocrine Practice"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00125-005-1717-3","article-title":"Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)","volume":"48","author":"Clarke","year":"2005","journal-title":"Diabetologia"},{"issue":"7369","key":"10.1002\/14651858.CD006127.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/bmj.325.7369.860","article-title":"Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63)","volume":"325","author":"Gray","year":"2002","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1464-5491.2001.00485.x","article-title":"An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 54)","volume":"18","author":"Gray","year":"2001","journal-title":"Diabetes Medicine"},{"issue":"15","key":"10.1002\/14651858.CD006127.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1464-5491.1994.tb00352.x","article-title":"Hypertension in Diabetes Study III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and \u03b2-blockade","volume":"11","author":"Hypertension in Diabetes Study Group","year":"1994","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s001250050614","article-title":"Hypertension in Diabetes Study IV.\u00a0Therapeutic requirements to maintain tight blood pressure control","volume":"39","author":"Hypertension in Diabetes Study Group","year":"1996","journal-title":"Diabetologia"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s001250051278","article-title":"Microaneurysms in the development of diabetic retinopathy (UKPDS 42)","volume":"42","author":"Kohner","year":"1999","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme-12647","article-title":"The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)","volume":"32","author":"lva","year":"2015","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"issue":"9131","key":"10.1002\/14651858.CD006127.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/bmj.317.7160.720","article-title":"Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2337\/diacare.22.7.1125","article-title":"Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)","volume":"22","author":"UK Prospective Diabetes Study Group","year":"1999","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/archopht.122.11.1631","article-title":"Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. UKPDS 69","volume":"122","author":"UK Prospective Diabetes Study Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance","volume":"34","author":"UK Prospective Diabetes Study Group","year":"1991","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0113|cit113","first-page":"287","article-title":"Treatment effects of captopril on non-proliferative diabetic retinopathy","volume":"125","author":"Wang","year":"2012","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"Article ID 3646","DOI":"10.1155\/2020\/3646342","article-title":"Analysis of the effect of nine consecutive years\u2019 intensive management and number of times achieving the target control on endpoint events in T2DM patients in Sanlitun Community Health Service Center in Beijing","volume":"2020","author":"Wan","year":"2020","journal-title":"International Journal of Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3390\/nu11071691","article-title":"Life style intervention improves retinopathy status\u2014The Finnish Diabetes Prevention Study","volume":"11","author":"Aro","year":"2019","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0116|cit116","unstructured":"Auyanet I Rodriguez LJ Esparza N Cabrera F Rossique P Suria S Does carvedilol minimize the requirements for laser photocoagulation in diabetic retinopathy? Nefrologia 2010 30 4 473 4"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3317\/jraas.2003.019","article-title":"Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design","volume":"4","author":"Andersen","year":"2003","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.2040-1124.2010.00085.x","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes: is blood pressure control the lower the better?","volume":"2","author":"Chang","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.287.19.2563","article-title":"Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus","volume":"287","author":"Genuth","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","article-title":"Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort","volume":"22","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group","year":"1999","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1002\/14651858.CD006127.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","article-title":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial","volume":"75","author":"The Diabetes Control and Complications Trial Research Group","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0123|cit123","first-page":"1085","article-title":"Evaluation of retinal involvement in type 2 diabetics with microalbuminuria","volume":"128","author":"Durruty","year":"2000","journal-title":"Revista Medica de Chile"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0124|cit124","first-page":"690","article-title":"Metabolic controlled trial of nicardipine in type 2 diabetic patients with slight hypertension","volume":"45","author":"Faguer de Moustier","year":"1989","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/diab.18.5.285","article-title":"A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy","volume":"18","author":"Harrold","year":"1969","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0126|cit126","first-page":"99","article-title":"Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy","volume":"24","author":"Jackson","year":"1992","journal-title":"Annals of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-011-2199-0","article-title":"Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS)","volume":"54","author":"Kawasaki","year":"2011","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00125-009-1622-2","article-title":"Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)","volume":"53","author":"Sone","year":"2010","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0129|cit129","first-page":"18","article-title":"On the prospective significance of age at onset of diabetes, metabolic control, and hypertension for the development of diabetic retinopathy in patients with IDDM","volume":"5","author":"Lehsten","year":"1996","journal-title":"Diabetes und Stoffwechsel"},{"issue":"9145","key":"10.1002\/14651858.CD006127.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy:\u00a0randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet"},{"issue":"7011","key":"10.1002\/14651858.CD006127.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/bmj.311.7011.973","article-title":"Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria","volume":"311","author":"Microalbuminuria Collaborative Study Group","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1755-3768.2009.01847.x","article-title":"Lack of effect of short-term treatment with amlodipine and lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy","volume":"89","author":"Mehlsen","year":"2011","journal-title":"Acta Ophthalmologica"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/112067219100100305","article-title":"The effect of beta blockers on retinal blood flow in diabetic patients","volume":"1","author":"Newsom","year":"1991","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/2009.60","article-title":"Rationale, design, and patient baseline characteristics of OlmeSartan and Calcium Antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients","volume":"32","author":"Ogawa","year":"2009","journal-title":"Hypertension Research"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD006127.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0026-0495(98)90368-7","article-title":"Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects","volume":"47","author":"Patel","year":"1998","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"B","key":"10.1002\/14651858.CD006127.pub3-BIB0136|cit136","first-page":"B22","article-title":"The benefits of angiotensin II receptor antagonists in high-risk hypertensive patients with diabetes","volume":"2","author":"Porush","year":"2000","journal-title":"European Heart Journal Supplements"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0953-6205(99)00068-0","article-title":"Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes","volume":"11","author":"Rachmani","year":"2000","journal-title":"European Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0138|cit138","first-page":"S207","article-title":"Effect of ACE-inhibitors on retinopathy score and retinal hemodynamics in normotensive diabetic subjects","volume":"38","author":"Rassam","year":"1997","journal-title":"American Academy of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ndt\/13.10.2547","article-title":"Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy","volume":"13","author":"Schwartz","year":"1998","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/JRAAS.2000.050","article-title":"Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor block (ARB) therapy","volume":"1","author":"Bedigian","year":"2000","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD006127.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0895-7061(00)00436-2","article-title":"Baseline characteristics of the hypertensive cohort of the appropriate blood pressure control in diabetes trial\u2014part 2 with valsartan (ABCD-2V)","volume":"13","author":"Bedigian","year":"2000","journal-title":"American Journal of Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjhyper.2006.05.011","article-title":"Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes","volume":"19","author":"Estacio","year":"2006","journal-title":"American Journal of Hypertension"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD006127.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"141A","DOI":"10.1016\/S0895-7061(99)80501-9","article-title":"ABCD-2V: Appropriate blood pressure control in diabetes\u2014part 2 with valsartan","volume":"12","author":"Shrier","year":"1999","journal-title":"American Journal of Hypertention"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.21.1.157","article-title":"Diabetic retinopathy","volume":"21","author":"American Diabetes Association","year":"1998","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008277.pub2","article-title":"Blood pressure targets for hypertension in people with diabetes mellitus","author":"Arguedas","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","article-title":"Prevalence and causes of visual impairment and blindness among Scandinavian adults: the Copenhagen City Eye Study","volume":"111","author":"Buch","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0147|cit147","unstructured":"Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","article-title":"Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22","volume":"114","author":"Chew","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"12A","key":"10.1002\/14651858.CD006127.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD006127.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0151|cit151","doi-asserted-by":"crossref","unstructured":"Desai M Pratt LA Lentzner H Robinson KN Trends in vision and hearing among older Americans Aging Trends 2001 2 1 8","DOI":"10.1037\/e620682007-001"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006127.pub2","article-title":"Blood pressure control for diabetic retinopathy","author":"Do","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0154|cit154","first-page":"983","article-title":"Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report number 10","volume":"26","author":"Rand","year":"1985","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings","volume":"85","author":"The Diabetes Retinopathy Study Research Group","year":"1978","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000395330","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report number 5","volume":"2","author":"The Diabetic Retinopathy Study Research Group","year":"1981","journal-title":"Developments in Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0157|cit157","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report number 8","volume":"88","author":"The Diabetic Retinopathy Study Research Group","year":"1981","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archopht.122.4.552","article-title":"The prevalence of diabetic retinopathy among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/archopht.122.4.546","article-title":"The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States","volume":"122","author":"The Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub3-BIB0161|cit161","first-page":"786","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2014an extension of the modified Airlie House classification. ETDRS report number 10","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub3-BIB0163|cit163","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0164|cit164","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18","volume":"39","author":"Davis","year":"1998","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD006127.pub3-BIB0165|cit165","first-page":"766","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.1993.03500100088034","article-title":"How effective are treatments for diabetic retinopathy?","volume":"269","year":"1993","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006127.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2337\/diacare.27.2007.S84","article-title":"Retinopathy in diabetes","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra021678","article-title":"Medical progress: diabetic retinopathy","volume":"350","author":"Frank","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bjo.83.9.1083","article-title":"Hypertension and diabetic retinopathy\u2014what's the story?","volume":"83","author":"Gillow","year":"1999","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00417-004-0880-4","article-title":"Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Castedaccia Eye Study","volume":"242","author":"Giuffre","year":"2004","journal-title":"Graefe's Archives of Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0171|cit171","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bjo.73.2.88","article-title":"Blind and partial sight registration in Avon","volume":"73","author":"Grey","year":"1989","journal-title":"British Journal of Ophthalmology"},{"issue":"9118","key":"10.1002\/14651858.CD006127.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/diacare.21.8.1230","article-title":"Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type-2 diabetes? A US population study","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.0742-3071.2001.00603.x","article-title":"What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?","volume":"19","author":"Hayward","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0176|cit176","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"9200","key":"10.1002\/14651858.CD006127.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006127.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/PL00002935","article-title":"The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes","volume":"44","author":"Keen","year":"2001","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1984.01040030405011","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"19","key":"10.1002\/14651858.CD006127.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.1988.03410190112033","article-title":"Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy","volume":"260","author":"Klein","year":"1988","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0161-6420(89)32699-6","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy XI. The incidence of macular edema","volume":"96","author":"Klein","year":"1989","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/archinte.1989.00390110033008","article-title":"Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?","volume":"149","author":"Klein","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.86.4.365","article-title":"Blood pressure control and diabetic retinopathy","volume":"86","author":"Klein","year":"2002","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0161-6420(02)01074-6","article-title":"The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study","volume":"109","author":"Klein","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/diacare.26.1.76","article-title":"Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes","volume":"26","author":"Krakoff","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000027415","article-title":"Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern","volume":"213","author":"Krumpaszky","year":"1999","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1002\/14651858.CD006127.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1464-5491.2002.00839.x","article-title":"Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with type 1 diabetes","volume":"19","author":"Kullberg","year":"2002","journal-title":"Diabetes Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0161-6420(03)00086-1","article-title":"Incidence of diabetic retinopathy in the Barbados Eye Studies","volume":"110","author":"Leske","year":"2003","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy. A systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD006127.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0161-6420(96)30486-7","article-title":"Cigarette smoking and ten-year progression in diabetic retinopathy","volume":"103","author":"Moss","year":"1996","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD006127.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s001250100030","article-title":"Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study","volume":"44","author":"Porta","year":"2001","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0194|cit194","unstructured":"Preferred Practice Patterns\u00ae Guidelines. Diabetic Retinopathy San Francisco, CA American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD006127.pub3-BIB0195|cit195","unstructured":"Review Manager (RevMan) Nordic Cochrane Center, The Cochrane Collaboration 2020"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0420.1996.tb00716.x","article-title":"Current trends in newly registered blindness in Denmark","volume":"74","author":"Rosenberg","year":"1996","journal-title":"Acta Ophthalmologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD006127.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.survophthal.2012.01.004","article-title":"Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective","volume":"57","author":"Sivaprasad","year":"2012","journal-title":"Survey of Opthalmology"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1742-1241.2010.02552.x","article-title":"Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review","volume":"65","author":"Sj\u00f8lie","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0199|cit199","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008214.pub2","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2337\/diacare.26.6.1731","article-title":"The prevalence of and factors associated with diabetic retinopathy in the Australian population","volume":"26","author":"Tapp","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/bjophthalmol-2013-304017","article-title":"Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service","volume":"99","author":"Thomas","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"9131","key":"10.1002\/14651858.CD006127.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD006127.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD006127.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diacare.25.8.1320","article-title":"Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn Study","volume":"25","author":"Leiden","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD006127.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.121.2.245","article-title":"Risk factors for incident retinopathy in a diabetic and non-diabetic population: The Hoorn Study","volume":"121","author":"Leiden","year":"2003","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD006127.pub3-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006127.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD006127.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2337\/diacare.24.7.1275","article-title":"Risk of developing retinopathy in Diabetes Control and Complication Trial type 1 diabetic patients with good or poor metabolic control","volume":"24","author":"Zhang","year":"2001","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD006127.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the United States, 2005-2008","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006127.pub3-BIB0210|cit210","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006127.pub2","article-title":"Blood pressure control for diabetic retinopathy","author":"Do","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006127.pub3-BIB0211|cit211","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006127","article-title":"Blood pressure control for diabetic retinopathy","author":"Sleilati","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:41:51Z","timestamp":1760557311000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006127.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":211,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006127.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}